Characteristics of patients age 40 y or older and association with telomere length quartiles
| . | Telomere length quartile . | . | ||
|---|---|---|---|---|
| . | Shortest, n = 317 . | Intermediate (2nd and 3rd), n = 633 . | Longest, n = 317 . | P . |
| Patient-related variable | ||||
| Age at transplantation, median (range), y | 61 (40-77) | 61 (40-77) | 60 (40-76) | .12* |
| Female, n (%) | 99 (31) | 251 (40) | 146 (46) | <.001† |
| Karnofsky performance status score <90, n (%) | 99 (31) | 196 (31) | 87 (27) | .11† |
| Disease-related variable | ||||
| Hemoglobin, median (IQR), g/dL | 9.0 (8.0-10.4) | 9.6 (8.2-11.4) | 9.8 (8.4-11.5) | <.001* |
| Platelet count, median (IQR), ×109/L | 53 (20-99) | 83 (34-160) | 96 (50-159) | <.001* |
| Absolute neutrophil count, median (IQR), ×109/L | 0.9 (0.4-1.7) | 1.2 (0.6-2.3) | 1.6 (0.7-2.8) | <.001* |
| Bone marrow blasts, median (IQR), % | 3 (1-7) | 3 (1-5) | 3 (1-5) | .27* |
| IPSS-R cytogenetic risk group, n (%) | .62‡ | |||
| Very good | 3 (1) | 3 (0) | 3 (1) | |
| Good | 116 (37) | 249 (39) | 126 (40) | |
| Intermediate | 51 (16) | 93 (15) | 48 (15) | |
| Poor | 52 (16) | 105 (17) | 45 (14) | |
| Very poor | 29 (9) | 56 (9) | 27 (9) | |
| Unknown | 66 (21) | 127 (20) | 68 (21) | |
| Prior MDS-directed therapy, n (%) | 186 (59) | 424 (67) | 201 (63) | .08† |
| Therapy-related MDS, n (%) | 79 (25) | 122 (19) | 68 (21) | .29† |
| Time from diagnosis to HSCT, median (IQR), mo | 9.5 (5.5-23.7) | 8.2 (5.4-15.5) | 8.4 (5.4-16.5) | .13* |
| Transplantation-related variable | ||||
| Conditioning regimen, n (%) | .70† | |||
| Myeloablative | 140 (44) | 291 (46) | 151 (48) | |
| Reduced intensity | 145 (46) | 274 (43) | 136 (43) | |
| Nonmyeloablative | 28 (9) | 64 (10) | 29 (9) | |
| Missing | 4 (1) | 4 (1) | 1 (0) | |
| Donor type, n (%) | .39† | |||
| Matched, related | 35 (11) | 84 (13) | 46 (15) | |
| Matched, unrelated | 188 (59) | 380 (60) | 187 (59) | |
| Mismatched | 71 (22) | 113 (18) | 58 (18) | |
| Cord blood | 23 (7) | 56 (9) | 26 (8) | |
| Graft type, n (%) | .73† | |||
| Bone marrow | 41 (13) | 78 (12) | 38 (12) | |
| Peripheral blood stem cells | 251 (79) | 497 (79) | 253 (80) | |
| Cord blood | 22 (7) | 54 (9) | 25 (8) | |
| Other | 3 (1) | 4 (1) | 1 (0) | |
| In vivo T-cell depletion, n (%) | .38† | |||
| No | 178 (56) | 356 (56) | 162 (51) | |
| Yes | 129 (41) | 248 (39) | 136 (43) | |
| Missing | 10 (3) | 29 (5) | 19 (6) | |
| GVHD prophylaxis, n (%) | .99† | |||
| Tacrolimus-based | 245 (77) | 502 (79) | 242 (76) | |
| Cyclosporine A-based | 39 (12) | 80 (13) | 41 (13) | |
| Other | 10 (3) | 18 (3) | 9 (3) | |
| CD34 selection | 8 (3) | 13 (2) | 8 (3) | |
| Ex vivo T-cell depletion | 5 (2) | 7 (1) | 4 (1) | |
| Cyclophosphamide-based | 4 (1) | 8 (1) | 5 (2) | |
| None reported | 6 (2) | 5 (1) | 8 (3) | |
| . | Telomere length quartile . | . | ||
|---|---|---|---|---|
| . | Shortest, n = 317 . | Intermediate (2nd and 3rd), n = 633 . | Longest, n = 317 . | P . |
| Patient-related variable | ||||
| Age at transplantation, median (range), y | 61 (40-77) | 61 (40-77) | 60 (40-76) | .12* |
| Female, n (%) | 99 (31) | 251 (40) | 146 (46) | <.001† |
| Karnofsky performance status score <90, n (%) | 99 (31) | 196 (31) | 87 (27) | .11† |
| Disease-related variable | ||||
| Hemoglobin, median (IQR), g/dL | 9.0 (8.0-10.4) | 9.6 (8.2-11.4) | 9.8 (8.4-11.5) | <.001* |
| Platelet count, median (IQR), ×109/L | 53 (20-99) | 83 (34-160) | 96 (50-159) | <.001* |
| Absolute neutrophil count, median (IQR), ×109/L | 0.9 (0.4-1.7) | 1.2 (0.6-2.3) | 1.6 (0.7-2.8) | <.001* |
| Bone marrow blasts, median (IQR), % | 3 (1-7) | 3 (1-5) | 3 (1-5) | .27* |
| IPSS-R cytogenetic risk group, n (%) | .62‡ | |||
| Very good | 3 (1) | 3 (0) | 3 (1) | |
| Good | 116 (37) | 249 (39) | 126 (40) | |
| Intermediate | 51 (16) | 93 (15) | 48 (15) | |
| Poor | 52 (16) | 105 (17) | 45 (14) | |
| Very poor | 29 (9) | 56 (9) | 27 (9) | |
| Unknown | 66 (21) | 127 (20) | 68 (21) | |
| Prior MDS-directed therapy, n (%) | 186 (59) | 424 (67) | 201 (63) | .08† |
| Therapy-related MDS, n (%) | 79 (25) | 122 (19) | 68 (21) | .29† |
| Time from diagnosis to HSCT, median (IQR), mo | 9.5 (5.5-23.7) | 8.2 (5.4-15.5) | 8.4 (5.4-16.5) | .13* |
| Transplantation-related variable | ||||
| Conditioning regimen, n (%) | .70† | |||
| Myeloablative | 140 (44) | 291 (46) | 151 (48) | |
| Reduced intensity | 145 (46) | 274 (43) | 136 (43) | |
| Nonmyeloablative | 28 (9) | 64 (10) | 29 (9) | |
| Missing | 4 (1) | 4 (1) | 1 (0) | |
| Donor type, n (%) | .39† | |||
| Matched, related | 35 (11) | 84 (13) | 46 (15) | |
| Matched, unrelated | 188 (59) | 380 (60) | 187 (59) | |
| Mismatched | 71 (22) | 113 (18) | 58 (18) | |
| Cord blood | 23 (7) | 56 (9) | 26 (8) | |
| Graft type, n (%) | .73† | |||
| Bone marrow | 41 (13) | 78 (12) | 38 (12) | |
| Peripheral blood stem cells | 251 (79) | 497 (79) | 253 (80) | |
| Cord blood | 22 (7) | 54 (9) | 25 (8) | |
| Other | 3 (1) | 4 (1) | 1 (0) | |
| In vivo T-cell depletion, n (%) | .38† | |||
| No | 178 (56) | 356 (56) | 162 (51) | |
| Yes | 129 (41) | 248 (39) | 136 (43) | |
| Missing | 10 (3) | 29 (5) | 19 (6) | |
| GVHD prophylaxis, n (%) | .99† | |||
| Tacrolimus-based | 245 (77) | 502 (79) | 242 (76) | |
| Cyclosporine A-based | 39 (12) | 80 (13) | 41 (13) | |
| Other | 10 (3) | 18 (3) | 9 (3) | |
| CD34 selection | 8 (3) | 13 (2) | 8 (3) | |
| Ex vivo T-cell depletion | 5 (2) | 7 (1) | 4 (1) | |
| Cyclophosphamide-based | 4 (1) | 8 (1) | 5 (2) | |
| None reported | 6 (2) | 5 (1) | 8 (3) | |